| Abstrakt: |
Summary A total of 4,166 (17.4%) strains of Group D streptococci were recovered from 27,474 surveillance samples taken from the nose, throat, gingiva, axilla, and rectum of patients at a cancer center. An additional 2,217 strains were recovered from 7,106 urine samples and 58 strains from 5,286 blood samples. Approximately 11% of gingival cultures yielded Group D streptococci.Streptococcus faecalis was most prevalent, followed byStreptococcus bovis, Streptococcus faecium, Streptococcus avium, Streptococcus equinus, andStreptococcus durans. Six of the 11 premortem blood cultures positive forS. faecalis grew other organisms as well, chiefly gram negative bacilli. The sevenS. faecalis recovered from postmortem bloods all occurred together with gram-negative bacilli or yeasts. Abscesses and lesions had recovery rates of 7.9% and 13.2%, respectively.S. faecium was the Group D streptococcus resistant to the most antibiotics andS. bovis was the most susceptible. Although most strains were only moderately susceptible to penicillin by disc susceptibility tests, minimum inhibitory concentrations of representative strains were in the susceptible range. Ampicillin susceptibilities ranged from 71% to 93%. About half of theS. faecium andS. avium strains were resistant to carbenicillin, but the other species were more susceptible. Vancomycin, furadantin, and chloramphenicol all had = 82% susceptibilities to Group D streptococci. The widely divergent antibiotic susceptibilities of the Group D streptococci makes their specific susceptibility tests an essential part of optimal patient care. |
Full text from SpringerLink